Why US drug ads are on TV (and almost nowhere else)

In many countries you mostly see ads for over-the-counter remedies, insurers, or cough syrup. In the United States, the evening news cuts to a spot that names a prescription drug, a condition, a smile… then a rapid-fire list of side effects. That is not vague culture. It is a rare regulatory exception.

Direct-to-consumer (DTC) advertising

DTC means the manufacturer speaks to the public, not only to clinicians. For prescription medicines, most countries ban or tightly restrict this kind of advertising (especially on TV). The United States allows it under FDA rules. New Zealand is the other developed-country case often cited — under a different regime.

Elsewhere, promotion stays mostly professional (sales calls, specialist press), sometimes with “ask your doctor” campaigns that never name the product.

What the FDA requires (in outline)

For a “product claim” ad that names the drug and its use, the FDA expects, among other things:

• benefit claims that are not misleading,
• a presentation of major risks (contraindications, important side effects) — the familiar fair balance,
• for TV/radio: a “major statement” on risks, with stronger rules that it be clear, conspicuous, and neutral (the CCN rule, with a recent compliance timeline).

The FDA does not pre-clear every spot like a mandatory visa; it regulates, guides, and can act after the fact. So ads can be legal — and still criticized for tone or the pace of the disclaimer.

Why it exists in the US (and not where you live)

Several levers, without cartoon villains:

1. Legal frame: prescription advertising is not banned by default; it is constrained.
2. Market: high prices, fragmented private insurance, patients who “ask” for a drug they saw on TV — ad ROI can be huge.
3. Culture: the informed patient-consumer as an ideal; the real risk is induced or anxiety-driven demand.
4. First Amendment: commercial speech has partial constitutional protection in the U.S., which complicates total bans.

WHO guidance and many national regulators start from the opposite instinct: keep promotion of prescription medicines cautious and mostly professional — hence the global gap.

What you hear (and what you don’t)

U.S. spots often run three beats: a condition made ordinary or dramatic, a soft-lit return to “normal life,” then the risk list. The format is not neutral: it must fit benefits + risks into ad time. Hence the absurdist effect — joyful dancing plus “may cause…” in voice-over.

What the spot almost never makes clear enough for a lay viewer:

• price (often high, insurance-dependent),
• alternatives (other molecules, generics, non-drug options),
• that an approved drug cleared trials… without being optimal for you.

“Reminder” ads (brand name, no indication) and “help-seeking” ads (condition, no brand) follow different rules; the public often blends all three.

Pressure on the clinician, not only the couch

The goal is not only brand awareness. It is demand in the exam room: “Doctor, I saw drug X.” Public-health studies disagree on exact magnitude, but the mechanism is clear: ads move part of the treatment agenda into the living room. Some call that patient empowerment; others call it marketing that skews clinical talk. Both readings can be true depending on the product and the patient.

In Europe, where prescription DTC on TV is largely closed, the debate sits elsewhere (detailing, gray-zone digital influence, OTC ads). The American exception makes visible what other systems keep backstage. None of this requires assuming bad faith in every commercial — only noticing that TV is allowed to recruit patients in a way most peers forbid.

How to read it without a conspiracy

A TV ad is neither a prescription nor proof the drug is right for you. It is a commercial message under constraints. Useful decisions still run through label, clinician, alternatives, cost. Knowing why the spot exists avoids two extremes: “banned elsewhere so it must be evil” and “it’s on TV so it’s safe.”

If you live in the U.S.: note the name, read the FDA label materials, and treat the on-screen smile as what it is — an ad. If you are watching from Europe: the culture shock is fair; it mainly shows how open the patient channel is there.

Going further

• FDA — Basics of drug ads: ad types and requirements.
• FDA — Prescription drug advertising: regulatory hub.
• Federal Register — major statement CCN: TV/radio risk-statement rule.
• WHO — Ethical criteria for medicinal drug promotion: international ethical frame (restrictive orientation).